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Background: First-line therapy for primary open-angle glaucoma and ocular hypertension 
generally involves prostaglandin analogue therapy. The relative efficacy of differing prosta-
glandin therapy is disputed.
Methods: A meta-analysis was conducted of head-to-head randomized trials of prostaglandin 
therapies. We included randomized trials assessing head-to-head evaluations of prostaglandin 
analogues travoprost, latanoprost and bimatoprost in patients with predominantly primary 
open-angle glaucoma or ocular hypertension. Findings were interpreted in light of equivalence 
margins.
Results: Our search identified 16 eligible trials, of which 15 were included in the meta-analysis. 
Trials were, in general, poorly reported. We pooled 9 trials assessing IOP-lowering effects of 
travoprost vs latanoprost (total n = 1098, weighted mean difference [WMD], –0.24 mmHg, 
95% CI, –0.87 to 0.38, P = 0.45, I2 = 56%, 95% CI, 0 to 0.77, heterogeneity P = 0.01). Eight 
trials assessed travoprost vs bimatoprost (total n = 714, WMD, 0.88 mmHg, 95% CI, 0.13 to 
1.63, P = 0.02, I2 = 56%, 95% CI, 0% to 78%, heterogeneity P = 0.02). And 8 trials assessed 
latanoprost vs bimatoprost (total n = 943, WMD, 0.73 mmHg, 95% CI, 0.10 to 1.37, P = 0.02, 
I2 = 47%, 95% CI, 0% to 74%, heterogeneity P = 0.06). Travoprost was associated with 
greater incidence of conjunctival hyperemia than latanoprost (RR 5.71, 95% CI, 1.81 to 18.02, 
P  0.001, I2 = 97%, 95% CI, 95 to 98, P  0.001). Five trials assessing latanoprost and bima-
toprost revealed an elevated risk of conjunctival hyperemia with bimatoprost (RR 1.59, 95% 
CI, 1.02 to 2.48, P = 0.04, I2 = 76%, 95% CI, 16 to 88, P = 0.002).
Conclusion: Randomized head-to-head evaluations of prostaglandin therapy demonstrate 
similar efficacy effects, but differing hyperemia effects.
Keywords: prostaglandin analogues, primary open-angle glaucoma, ocular hypertension, 
travoprost, latanoprost, bimatoprost
Background
Primary open-angle glaucoma (POAG) is a progressive optic neuropathy characterized 
by acquired loss of retinal ganglion cells and atrophy of the optic nerve and is a 
leading cause of blindness in both the developed and developing world.1 Elevated 
intraocular pressure (IOP) has been identified as a major risk factor for primary 
open-angle glaucoma and thus drugs that reduce IOP have the potential to prevent or 
delay optic nerve damage and prolong vision.2,3 The Ocular Hypertension Treatment 
Study, a large randomized trial of 1636 participants with elevated IOP, that com-
pared topical medication use with only observation found important decreases in IOP 
(mean decrease in active group of 22.5%, standard deviation [SD] 9.9%, compared Clinical Ophthalmology 2009:3 448
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to a mean decrease of 4.0% in the observation group, SD 
11.6%) with topical medication use and a large decrease in 
progression to POAG (hazard ratio, 0.40, 95% confidence 
interval [CI] 0.27–0.59, P  0.0001) over 5 years. The 
extent to which individual topical agents exerted differing 
therapeutic effects in the trial is, however, unknown.4,5 Of 
all current therapies utilized in the treatment of POAG 
associated with raised IOP, prostaglandin analogues (PGAs) 
demonstrate consistent superiority over beta-adrenergic 
blockers (eg, betaxolol), alpha-adrenergic agonists (eg, 
brimonidine) or a topical carbonic anhydrase inhibitor 
(dorzolamide) therapies as far as IOP-lowering efficacy 
is concerned.6–8 More invasive treatment strategies, such 
as surgery, may be effective, but also can result in severe 
adverse events and population-heavy costs.9,10 Prostaglandin 
analogues lower IOP by increasing the uveoscleral outflow 
of aqueous humor.7 They are effective in reducing IOP and 
have the additional advantage of requiring only once a day 
administration.11
Current prostaglandin therapies available in the United 
States and United Kingdom include bimatoprost (0.03%), 
latanoprost (0.005%), and travoprost (0.004%). Although 
there is extensive evidence on the efficacy of the individual 
prostaglandin drugs, data determining the comparative 
effectiveness of the three drugs are sparse.11
We aimed to undertake a rigorous systematic review 
of the literature to identify randomized trials evaluating 
the head-to-head effectiveness of PGAs in the treatment 
of POAG and ocular hypertension and to conduct a 
meta-analysis of their results to improve understanding of 
the drugs’ relative efficacy.
Methods
Eligibility criteria
We included any randomized trial that evaluated bimatoprost 
(0.03%), latanoprost (0.005%), or travoprost (0.004%). We 
included randomized trials of at least 3 months’ duration. 
Studies had to compare a prostaglandin, for the purpose of 
affecting any of the following clinically important glaucoma 
and ocular hypertension outcomes: IOP; response rates; 
and adverse events. With the presence of head-to-head 
evaluations, we excluded studies comparing prostaglandins to 
other glaucoma treatments, dose-finding studies, cross-over 
trials, and short-term evaluations.
search strategy
We established a search strategy based on the Medi-
cal Subject Headings [MeSH] and clinical outcomes. 
We searched independently the following databases (from 
inception to May 2008): MEDLINE, EMBASE, and 
Cochrane CENTRAL. We additionally searched conference 
abstracts via Greynet.org. Finally, we searched Web of 
Science, a database that included the full text of journals 
(OVID, Science Direct, and Ingenta, including articles in full 
text from approximately 1700 journals since 1993). In addi-
tion, we searched the bibliographies of published systematic 
reviews6,8,10–14 and American Academy of Ophthalmology 
guidelines.15 We also contacted the authors of trials for study 
clarifications, where required. Searches were not limited by 
language, sex, or age.
study selection
Three investigators (OE, EM, BR), working independently, 
scanned all abstracts, and obtained the full-text reports of 
records, which indicated or suggested that the study was a 
randomized trial evaluating PGA therapy in a head-to-head 
design. After obtaining full reports of the candidate trials 
(either in a full peer-reviewed publication or press article) 
the same reviewers independently assessed eligibility from 
full-text papers.
Data collection
The same reviewers conducted data extraction independently 
using a standardized pre-piloted form. Reviewers collected 
information about the PGAs, the population studied (age, sex, 
underlying conditions), and the treatment effect on specified 
outcomes: IOP changes, response rates, adverse events, and 
the length of follow-up. Study evaluation included general 
methodological quality features assessing methods of ran-
domization, allocation concealment, use of intention-to-treat 
analysis, and methods of blinding.16,17 Because most head-to-
head trials are designed to demonstrate equivalence,18 we also 
noted whether the authors had denoted an a priori margin of 
equivalence (ρ).19,20 We entered the data into an electronic 
database such that triplicate entries existed for each study; 
when the entries did not match, we resolved differences 
through discussion and consensus.
Data analysis
In order to assess inter-rater reliability on inclusion of 
articles, we calculated the Phi statistic, which provides 
a measure of inter-observer agreement independent of 
chance.21 For the primary outcome of IOP-lowering effects 
between groups at study completion, we calculated the 
weighted mean difference (WMD) across studies using the 
DerSimonian-Laird random effects model, that recognizes Clinical Ophthalmology 2009:3 449
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and anchors studies as a sample of all potential studies, 
and incorporates an additional between-study component 
to the estimate of variability.22 Pooled differences over all 
time points were generally reported, but when absent we 
contacted the study authors and, if no response, assumed the 
time point closest to 8 am as the primary time point. When 
authors reported standard deviations, we used them directly. 
When standard deviations were unavailable, we computed 
them from the standard errors or the test statistics if exact 
p-values were provided.
For response rates and adverse events of hyperemia, we 
calculated the relative risk [RR] and appropriate 95% CIs 
of outcomes according to the number of events reported in 
the original studies. In the event of zero outcome events in 
one arm of a trial, we used the Haldane method and added 
0.5 to each arm.23 We calculated the I2 statistic for each 
analysis as a measure of the proportion of the overall varia-
tion that is attributable to between-study heterogeneity, with 
appropriate 95% CIs. To investigate the association between 
study duration and IOP-lowering effects, we conducted a 
weighted meta-regression for study characteristics using 
the unrestricted maximum likelihood model.24 We chose 
this co-variate as we believed it is likely to influence trial 
outcomes beyond chance. Forest plots are displayed for each 
PGA analysis, showing individual study WMD with 95% 
CIs, and the overall DerSimmonian-Laird pooled estimate. 
We considered equivalence if both upper and lower 95% 
CIs for the pooled analysis were within 1.5 mmHg of zero 
difference, as is a commonly used margin of equivalence.25 
Analyses were conducted using STATA (version 9, www.
stata.com) and StatsDirect (v.2.6.5, www.statsdirect.com, 
Manchester).
Results
Our initial database searches identified a total of 1144 
abstracts. After a thorough assessment, 215 abstracts 
were excluded since they were review articles. Another 
549 abstracts were excluded as they were not relevant to 
present study. Overall, 380 full-text papers were retrieved 
in full-text for possible inclusion. Upon careful review of 
the 380 full-text articles, we included 15 full text articles 
and 1 conference abstract in our analysis. During the review 
process, we were able to add one study26 and removed 
another,27 that was an early report of the later publication. 
Figure 1 presents details of the exclusion criteria at the 
various stages during the study selection process. Five trials 
had more than 2 intervention arms,28–32 hence 9 trials assessed 
travoprost versus latanoprost,28–36 8 examined travoprost 
1144 potential relevant abstracts identified
380 full-text articles obtained
16 RCTs included
215 review articles excluded
549 irrelevant articles
37 articles excluded:
• 321 not randomized/not head to 
  head
• 13 duplicate
• 21 irrelevant
• 11 dosing evaluations
1 conference abstract added
1 added during review
   process
Figure 1 Flow diagram of included studies.Clinical Ophthalmology 2009:3 450
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versus bimatoprost,26,28–32,37,38 and 8 of latanoprost versus 
bimatoprost.28–32,39–41 We did not pool the data from one trial, 
reported as an abstract, as we were unable to determine the 
group sizes.42 Table 1 and 2 report the study characteristics 
and quality (see Tables 1 and 2). As demonstrated in Table 2, 
studies were of moderate to low quality.
Primary outcomes, iOP-lowering effects
Table 3 presents IOP-lowering effects at the study conclusion 
for all included trials. We pooled 9 trials assessing travoprost 
to latanoprost (total n = 1098, Figure 2). The weighted mean 
difference across groups is –0.24 mmHg (95% CI, –0.87 
to 0.38, P = 0.45, I2 = 56%, 95% CI, 0 to 0.77, heterogeneity 
P = 0.01). When we pooled 8 trials assessing travoprost to 
bimatoprost (total n = 688, Figure 3), we found a pooled 
weighted mean difference of 0.88 mmHg, 95% CI, 0.13 to 
1.63, P = 0.02, I2 = 56%, 95% CI, 0 to 78). Finally, we pooled 
8 trials assessing latanoprost with bimatoprost (total n = 974, 
Figure 4), we found a pooled weighted mean difference of 
0.73 mmHg (95% CI, 0.10 to 1.37, P = 0.02, I2 = 47%, 95% 
CI, 0 to 74, heterogeneity P = 0.06). Study duration was not 
associated with therapeutic effects (B coefficient –0.21, 95% 
CI, –0.33 to 1.09).
Response rates
Response rates were defined in 8 trials, but were not 
defined uniformly across these trials (Table 4). Response 
rates were pooled across studies when the definition was 
deemed similar enough. Two trials comparing travoprost 
to latanoprost provided a pooled RR of 1.15 (95% CI, 
0.99 to 1.33, P = 0.07). Three trials comparing travoprost 
to bimatoprost had a pooled RR of 0.82 (95% CI, 0.71 to 
0.95, P = 0.009, I2 = 0%, 95% CI, 0 to 72, P = 0.88). Three 
trials comparing latanoprost to bimatoprost provided a 
pooled RR of 0.98 (95% CI, 0.76–1.26, P = 0.87, I2 = 78, 
95% CI, 0 to 91, P = 0.01).
Conjunctival hyperemia
Six trials reporting hyperemia outcomes for travoprost 
and latanoprost were pooled. Travoprost was associated 
with conjunctival hyperemia significantly more than 
latanoprost (RR 5.71, 95% CI, 1.81 to 18.02, P  0.001, 
I2 = 97%, 95% CI, 95 to 98, P  0.001). In a single trial 
of travoprost and bimatoprost, there was a decreased risk 
of conjunctival hyperemia with bimatoprost (RR 0.82, 
95% CI, 0.69 to 0.97, P = 0.02). Finally, pooling five 
trials assessing latanoprost and bimatoprost revealed an 
Table 1 Characteristics of included studies
Author,  year TRAV n LAT n BIM n Duration 
(months)
Mean age Sex (M/F) Types of glaucoma TRAV dose LAT dose BIM dose
POAG OH Other
Arcieri 200532 17 15 16 6 67 34/30 34 0 30 0.004% 0.005% 0.03%
Cantor 200626 81 76 6 65 81/76 108 48 1 0.004% 0.03%
Cardascia 200334 9 9 6 52 9/9 18 nA nA
Cellini 200430 20 20 20 6 64 32/28 60 0.004% 0.005% 0.03%
Dirks 200639 27 33 3 71 21/39 60 0.005% 0.03%
Gandolfi 200140 113 119 3 62 87/145 132 81 13 0.004% 0.005% 0.03%
hepsen 200729 15 15 15 62 20/25 45 0.004% 0.005% 0.03%
Koz 200728 20 20 20 6 53 35/25 36 24 0.004% 0.005% 0.03%
Mundorf 200442
3 0.004% 0.03%
netland 200136 197 193 12 64 392/395 530 247 10 0.004% 0.005%
noecker 2003a41 136 133 6 61 103/166 150 93 26 0.005% 0.03%
noecker 2003b38 15 16 3 65 11/20 28 3 0.004% 0.03%
noecker 200637 45 49 3 63 37/57 67 27 0.004% 0.03%
Parmaksiz 200635 18 16 6 67 25/25 50 0.004% 0.005%
Parrish 200331 138 136 136 3 65 172/238 309 95 6 0.004% 0.005% 0.03%
Topouzis 200733 168 72 12 65 136/196 233 64 36 0.004% 0.005%
Abbreviations: TRAV, travoprost; LAT, latanoprost; BiM, bimatoprost; M/F, male/female; nA, data not available; POAg, primary open-angle glaucoma; Oh, ocular hypertension; 
Other, other types of chronic open angle glaucoma.Clinical Ophthalmology 2009:3 451
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elevated risk of conjunctival hyperemia with bimatoprost 
(RR 1.59, 95% CI, 1.02–2.48, P = 0.04, I2 = 76%, 95% 
CI, 16 to 88, P = 0.002).
Discussion
As the third leading preventable cause of blindness, glaucoma 
affects approximately 105 million people worldwide.1 The 
findings of this analysis should therefore be of interest to 
patients, clinicians, policy makers and health insurance funders. 
We found that all three PGA drugs produce similar efficacy, 
as measured by response rate and IOP-lowering, across a 
diverse population of POAG and ocular hypertension patients. 
The practical clinical importance of this finding is important as 
clinicians consult with patients about optimal interventions and 
consider issues of safety, long-term efficacy and cost.
This analysis has several strengths and limitations. 
Strengths include the extensive searches and contact with 
authors of the primary trial reports, as well as searches 
and data abstraction by three independent reviewers. Our 
analysis is limited as there may still be unpublished trials. 
We believe it is possible, and perhaps even likely, that 
negative studies have remained unpublished. It is possible 
that contacting companies may have identified unpublished 
studies; however, in our experience, companies do not 
openly share unpublished data. Another limitation is that 
reporting of methodological criteria was very inconsistent 
and definitions were not uniform. For example, responder 
outcomes were often not reported; of 16 included trials, 
only 9 reported responders, but used 7 different criteria for 
evaluating response rates. We found moderate heterogeneity 
in several analyses and were unable to explain it using a priori 
explanations, thus our inferences on the completeness of 
these estimates are weakened.
Some may disagree with our inclusion of a trial evaluating 
timolol plus travoprost versus timolol alone.33 We believe 
that such an evaluation meets our inclusion criteria of a pros-
taglandin versus an inert control as the prostaglandin effect 
here is the same relative effect as if it were prostaglandin 
versus nothing. We have conducted a sensitivity analysis to 
examine if our findings would differ on the primary outcome 
of IOP-lowering effects. When we examined travoprost 
versus latanoprost, we found a weighed mean difference 
of –0.17 (95% CI, –0.90 to 0.54, P = 0.63, I2 = 61%) mmHg, 
indicating no difference.
Interpreting noninferiority and equivalence studies may be 
challenging for readers. Figure 5 displays the recommended 
interpretation of confidence intervals for equivalence. Only 
7 trials reported their analysis as intent-to-treat. As these tri-
als were continuous outcomes and reported their changes by 
group, we were unable to calculate the intent-to-treat outcomes 
Table 2 Methodological issues in included studies
Author,  year Randomization Allocation concealment ITT Description of margin 
of equivalence
Blinding status
netland 200136 Yes Yes Yes Yes Yes
Arcieri 200532 Yes Yes no no Yes
Cantor 200626 Yes Yes Yes Yes Yes
Cardascia 200334 no no no no Yes
noecker 2003a41 Yes Yes Yes Yes Yes
Koz 200728 no no no Yes Yes
noecker 2003b38 Yes Unclear no no Yes
noecker 200637 Yes no Yes no Yes
Dirks 200639 Yes Unclear no no Yes
Gandolfi 200140 Yes Unclear Yes Yes Yes
Parrish 200331 Yes Yes Yes Yes Yes
Cellini 200430 Yes Unclear no no Yes
Parmaksiz 200635 Yes Unclear no no Yes
Mundorf 200442 no no no no Yes
hepsen 200729 no no no no Yes
Topouzis 200733 Yes no Yes – for 
safety analysis 
only
Yes Yes
Abbreviation: iTT, intention to treat.Clinical Ophthalmology 2009:3 452
Eyawo et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
for each trial. This issue is now receiving debate within the 
trial community and some argue that only studies reporting 
intent-to-treat be included.43 Without access to individual data, 
it is impossible to calculate intent-to-treat outcomes.
Our meta-analysis found equivalence across all three 
included drugs. Our findings stand in contrast to claims of 
superiority in the included studies. We are concerned with 
the general poor quality of included studies and the biased 
claims of superiority observed in the published reports. 
We found several instances where the primary outcomes 
were not significantly different, but the authors reported them 
as clinically important in their conclusions.33 Further, on 
average, the trials included in our analysis were small. There 
is a clear need for minimum sample sizes in equivalence 
trials of PGAs to avoid wasted resources and potentially 
spurious outcomes.
Initially, when the PGAs arrived on the market, 
beta-adrenergic blockers were widely considered first-line 
therapy in POAG and clinicians at that time decided to 
reserve the PGAs for cases where beta-blockers failed 
to reduce the IOP adequately.44 However over the past 
10 years the PGAs have emerged as the most popular 
first-line IOP-lowering class of drugs in the developed 
world.45 This approach is widely supported by international 
glaucoma societies. Guidelines generally advocate that if 
the first-choice therapy is not measurably effective on IOP, 
it is then preferable to change the initial therapy rather than 
switch to a different class drug. The issue of cost, however, 
still compels developing countries to reserve this class of drug 
for post-primary therapy or add-on treatment. As this study 
confirms equivalence between the three brands of PGAs, 
policy makers, especially in developing countries, may base 
their selection of a particular drug for public health programs 
on other practical issues such as cost alone.
As noncompliance with therapy plays a large role in 
progression to blindness, confirmation that all three drugs 
Table 3 Mean intraocular pressure (sD) outcomes for included 
studies
Author,  year Travoprost Latanoprost Bimatoprost
Arcieri 200532 14.20 (1.80) 14.90 (1.70) 14.30 (2.20)
Cantor 200626 18.70 (3.20) 17.50 (3.30)
Cardascia 200334 16.1 (1.9) 16.5 (1.7)
Cellini 200430 17.30 (2.3) 18.10 (2.3) 17.70 (3.8)
Dirks 200639 13.50 (3.30) 13.20 (3.30)
Gandolfi 200140 17.80 (3.04) 17.50 (3.04)
hepsen 200729 16.30 (3.2) 16.10 (3.2) 15.60 (3.2)
Koz 200728 20.9 (1.9) 20.8 (2.4) 18.3 (1.2)
Mundorf 200442 18.50 (3.30) 16.80 (3.30)
netland 200136 18.00 (4.22) 19.40 (3.97)
noecker 200341 18.20 (7.00) 16.8 (6.9)
noecker 200338 18.60 (9.50) 17.10 (9.50)
noecker 200637 17.70 (3.30) 17.10 (3.30)
Parmaksiz 200635 16.00 (2.80) 14.30 (1.90)
Parrish 200331 17.60 (3.70) 17.10 (3.10) 17.00 (3.30)
Topouzis 200733 17.10 (3.80) 17.70 (3.90)
Figure 2 Meta-analysis, travoprost versus latanoprost for iOP-lowering effects.
Effect size meta-analysis plot [random effects]
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are equally effective is encouraging. The favorable dosing 
schedule (once a day), acceptable side-effect profile and 
IOP-lowering efficacy make the PGAs highly favored 
among ophthalmologists and patients alike. Because dosing 
schedule, cost and treatment side-effects all have to be taken 
into account when choosing a therapy, the comparative 
conjunctival hyperemia side-effect of this class is important. 
Side-effects of the three different drugs are generally identical 
except for conjunctival hyperemia.
We found increased rates of conjunctival hyperemia 
associated with especially travoprost but also with 
bimatoprost as compared to latanoprost. Conjunctival 
Figure 3 Meta-analysis, travoprost versus bimatoprost for iOP-lowering effects.
−6 −1 0 4 9
Effect size meta-analysis plot [random effects]
Arcieri 200532
Cantor 200626
Cellini 200430
Hepsen 200729
Koz 200728
Noecker 200338
Noecker 200637
Parrrisha 200637
Table 4 Definition and outcomes among ‘Responders’ in included studies
Author,  year Definition of response Travoprost Latanoprost Bimatoprost RR 95% CI
Arcieri 200532 no measure
Cantor 200626 Reaching iOP of 20 mmhg 52/81 59/76 0.83 0.68–1.01
Cardascia 200334 no measure
Cellini 200430 no measure
Dirks 200639 if current regimen should 
continue
17/20 24/29 0.97 0.76–1.25
Gandolfi 200140 Reaching iOP of 17 mmhg 63/119 50/113 0.84 0.64–1.09
hepsen 200729 no measure
Koz 200728 no measure
Mundorf 200442 no measure
netland 200136 Reaching iOP of 17 mmhg 108/197 97/193 1.09 0.90–1.32
noecker 200341 At least 15% iOP decrease 98/136 118/133 1.23 1.09–1.39
noecker 200338 Reaching iOP 17 mmhg 8/15 9/16 0.95 0.50–1.80
noecker 200635 At least 20% iOP decrease 31/45 42/49 0.80 0.64–1.01
Parmaksiz 200635 no measure
Parrish 200331 no measure
Topouzis 200733 Reaching iOP 18 mmhg 86/168 68/164 0.91 0.71–1.16
Abbreviations: CI, confidence interval; IOP, intraocular pressure; RR, relative risk.Clinical Ophthalmology 2009:3 454
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Effect size meta-analysis plot [random effects]
Arcieri 200532
Cellini 200430
Dirks 200639
Gandolfi 200140
Hepsen 200729
Koz 200728
Noecker 200341
Parrish 200331
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Figure 4 Meta-analysis of latanoprost versus bimatoprost for iOP-lowering effects.
Figure 5 interpreting non-inferiority and equivalence trials.20 Error bars indicate 2-sided 95% confidence intervals (CI). Tinted area indicates zone of inferiority.   A, If the CI 
lies wholly to the left of zero, the new treatment is superior. B and C, if the Ci lies to the left of and includes zero, the new treatment is noninferior but not shown to be 
superior. D, If the CI lies wholly to the left of and wholly to the right of zero, the new treatment is noninferior in the sense already defined, but it is also inferior in the sense 
that a null treatment difference is excluded.   This puzzling case is rare, since it requires a very large sample size. it can also result from having too wide a noninferiority margin. 
E and F. If the CI includes and zero, the difference is nonsignificant but the result for noninferiority is inconclusive. G, If the CI includes and is wholly to the right of zero, the 
difference is statistically significant but the result is inconclusive for possible inferiority of magnitude or worse. H, If the CI is wholly above, the new treatment is inferior. 
Reproduced with permission from Piaggio g, Elbourne DR, Altman Dg, Pocock sJ, Evans sJ. Reporting of noninferiority and equivalence randomized trials: an extension of the 
COnsORT statement. JAMA. 2006; 295:1152–1160.20 Copyright © 2006 American Medical Association,  All rights reserved.Clinical Ophthalmology 2009:3 455
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hyperemia is of concern to clinicians for two main reasons: 
hyperemia may compromise the outcome of filtration 
surgery, and it may represent a cosmetic problem to the 
patient thereby likely to lead to poor treatment adherence.46 
The extent that hyperemia contributes to poor adherence 
and the effect of administration of the prostaglandin deriva-
tives on outcome filtration surgery remains to be deter-
mined. However, a recent evaluation examining reasons 
for patient discontinuation and poor adherence of PGA 
therapy found that hyperemia impacted almost two-thirds 
of patients with adverse events.47 Given that these evalu-
ations come from head-to-head trials, they provide strong 
inferences regarding clinical efficacy and public health 
implications. Conjunctival hyperemia appears to occur 
via a secondary mechanism, unrelated to the increased 
uveoscleral outflow mechanism induced by PGA therapy. 
While this effect may lessen over time,48 it may represent 
a cosmetic concern to the patient, that may lead to poor 
treatment adherence and thus poor outcomes.46 In gen-
eral, PGAs have few systemic adverse events and local 
ones are mainly transitory or reversible, supporting their 
use as first line therapy. Beta-blockers on the other side 
have a greater risk of systemic adverse events, but fewer 
local and cosmetic side-effects.46,48 Of note, adherence 
to treatment may depend on side-effects, but also on the 
frequency of instillation of the drops and the presence of 
preservative agents, the latter inducing a local reaction, 
that can have a negative effect on surgery, making the rate 
of success lower.49
Conclusions
PGAs remain powerful drugs in first-line therapy of open 
angle glaucoma and ocular hypertension. Clinicians and 
ophthalmologists choosing therapies should take into account 
the costs associated with individual drugs, their efficacy, 
the adverse events associated with them, and adherence to 
treatment.
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